Day: June 23, 2025

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) — Lucas GC Limited (NASDAQ: LGCL) (“Lucas” or the “Company”), an artificial intelligence (“AI”) technology-driven Platform-as-a-Service (“PaaS”) company with proprietary technologies applied to the human resources and insurance industry verticals, today announced the closing of its “best efforts” follow-on offering (the “Offering”) of 32,150,000 ordinary shares, par value US$0.000005 per share, of the Company (the “Ordinary Shares”) at a public offering price of US$0.20 per share, for total gross proceeds of US$6,430,000 before deducting placement agent’s fee and offering expenses. AC Sunshine Securities LLC acted as the placement agent for the Offering. A registration statement related to the Offering has been filed with, and declared effective by, the United...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) — StoneX Group Inc. (the “Company” or “StoneX”; NASDAQ: SNEX), today announced the pricing of a previously announced offering of $625.0 million in aggregate principal amount of 6.875% Senior Secured Notes due 2032 (the “Notes”) to be issued by its wholly-owned subsidiary, StoneX Escrow Issuer LLC. The Notes and the related Note guarantees are being offered in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain persons outside the United States pursuant to Regulation S under the Securities Act. The offering is expected to close on or about July 8, 2025, subject to customary closing conditions. StoneX Escrow Issuer LLC, which was created solely to issue...

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. J.P. Morgan, Morgan Stanley, Guggenheim Securities and Cantor...

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced the execution of an amended credit facility with Wells Fargo Bank, NA (“Wells Fargo”). This amendment modifies the current facility extending the term of the agreement to December 31, 2026 and modifies the borrowing capacity to $10 million. Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, “We are grateful for our long-standing relationship with Wells Fargo and we believe this amended credit facility is made possible by the strength of our balance sheet. We believe this facility will be sufficient to support our working capital needs as we continue to strive towards continued top-line...

ELKHART, Ind., June 23, 2025 (GLOBE NEWSWIRE) — THOR Industries, Inc. (NYSE: THO) today announced that its Board of Directors has retired the Company’s existing share repurchase authorization which was set to expire on July 31, 2025 and re-authorized the Company to repurchase up to $400 million of its Common Stock.  The Company may purchase shares on a discretionary basis from time to time through open market purchases, privately negotiated transactions or other means. The timing and amount of any transactions will be at the Company’s discretion subject to the market price of the stock, general market and economic conditions, cash availability, applicable legal requirements, and other growth investment opportunities. The repurchase authorization will expire July 31, 2027. “I am pleased to announce that THOR’s...

Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E. Martin Brenner, DVM, Ph.D., iBio’s CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic...

BETHESDA, MD, June 23, 2025 (GLOBE NEWSWIRE) — Alset Inc. (NASDAQ:AEI) (“AEI” or the “Company”), a diversified holding company principally engaged through its subsidiaries in the development of smart and sustainable home communities and other property development, financial services, digital transformation technologies, biohealth activities and consumer products, is pleased to announce that its Board of Directors has authorized a new stock repurchase program of up to $1,000,000 of the Company’s outstanding common stock. Repurchases under the program may be made through December 31, 2025, or until the authorized amount has been fully utilized, whichever occurs first. The Company has authorized its broker to implement this repurchase program and agreed that such broker will have complete discretion and control...